{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:35:23Z","timestamp":1791221723287,"version":"4.1.0"},"reference-count":62,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Digital patient monitoring (DPM) tools can enable more effective clinical care and improved patient outcomes in cancer. However, their broad adoption requires ease of use and demonstration of real-world clinical utility\/impact. ORIGAMA (MO42720) is an interventional, open-label, multicountry platform study investigating the clinical utility of DPM tools and specific treatments. ORIGAMA will begin with two cohorts that aim to assess the impact of the atezolizumab-specific Roche DPM Module (hosted on the Kaiku Health DPM platform (Helsinki, Finland)) on health outcomes and healthcare resource usage, and its feasibility to support at-home treatment administration, in participants receiving systemic anticancer treatment. Other digital health solutions may be added to future cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>In Cohort A, participants with metastatic non-small cell lung cancer (NSCLC), extensive-stage SCLC or Child Pugh A unresectable hepatocellular carcinoma will be randomised to a locally approved anticancer regimen containing intravenous atezolizumab (TECENTRIQ, F. Hoffmann-La Roche Ltd\/Genentech) and local standard-of-care support, with\/without the Roche DPM Module. Cohort B will assess the feasibility of the Roche DPM Module in supporting administration of three cycles of subcutaneous atezolizumab (1875\u2009mg; Day 1 of each 21-day cycle) in the hospital, followed by 13 cycles at home by a healthcare professional (ie, flexible care), in participants with programmed cell-death ligand 1-positive, early-stage NSCLC. The primary endpoints are the mean difference in change of the participant-reported Total Symptom Interference Score at Week 12 from baseline (Cohort A) and flexible care adoption rate at Cycle 6 (Cohort B).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study will be conducted according to the Declaration of Helsinki, and\/or the applicable laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study received its first Ethics Committee approval in Spain in October 2022. Participants will provide written informed consent in a face-to-face setting. The results of this study will be presented at national and\/or international congresses and disseminated via publication in peer-reviewed journals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05694013\">NCT05694013<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063242","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T10:46:50Z","timestamp":1681901210000},"page":"e063242","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05694013","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03735121","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05171777","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1075-1134","authenticated-orcid":false,"given":"Sanna","family":"Iivanainen","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Baird","sequence":"additional","affiliation":[{"name":"Trinity Translational Medicine Institute, Trinity College Dublin School of Medicine, Dublin, Ireland"},{"name":"Lung Cancer Europe, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Balas","sequence":"additional","affiliation":[{"name":"Product Development Safety, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bustillos","sequence":"additional","affiliation":[{"name":"Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo Yovanna","family":"Castro Sanchez","sequence":"additional","affiliation":[{"name":"Product Development Data Sciences, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Eicher","sequence":"additional","affiliation":[{"name":"Institute of Higher Education and Research in Health Care, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland"},{"name":"Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Golding","sequence":"additional","affiliation":[{"name":"Product Development Data Sciences, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathis","family":"Mueller-Ohldach","sequence":"additional","affiliation":[{"name":"Product Development Global, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Maria","family":"Reig","sequence":"additional","affiliation":[{"name":"BCLC Group, Liver Unit, Hospital Cl\u00ednic de Barcelona, IDIBAPS, Universidad de Barcelona, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical Care Center, Hospital Aschaffenburg GmbH, Aschaffenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4656-0949","authenticated-orcid":false,"given":"Johannes","family":"Ammann","sequence":"additional","affiliation":[{"name":"Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"2025101814421500000_13.4.e063242.1","unstructured":"World Health Organization (WHO), International Agency for Research on Cancer (IARC) . Global cancer observatory. 2022 Available: https:\/\/gco.iarc.fr\/"},{"key":"2025101814421500000_13.4.e063242.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"2025101814421500000_13.4.e063242.3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025101814421500000_13.4.e063242.4","doi-asserted-by":"crossref","DOI":"10.2196\/10875","article-title":"Electronic systems for patients to report and manage side effects of cancer treatment: systematic review","volume":"21","author":"Warrington","year":"2019","journal-title":"J Med Internet Res"},{"key":"2025101814421500000_13.4.e063242.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1073-9"},{"key":"2025101814421500000_13.4.e063242.6","first-page":"151","article-title":"Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers","volume":"23","author":"Van Laar","year":"2015","journal-title":"Support Care Cancer"},{"key":"2025101814421500000_13.4.e063242.7","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1002\/onco.13812","article-title":"The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"},{"key":"2025101814421500000_13.4.e063242.8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/OP.21.00727","article-title":"What oncologists must account for: the financial burden of cancer-associated symptom relief","volume":"18","author":"Giap","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2025101814421500000_13.4.e063242.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03420"},{"key":"2025101814421500000_13.4.e063242.10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healthpol.2020.11.011","article-title":"Cancer care at home or in local health centres versus in hospital: public policy goals and patients' preferences in the Rh\u00f4ne-Alps region in France","volume":"125","author":"Margier","year":"2021","journal-title":"Health Policy"},{"key":"2025101814421500000_13.4.e063242.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100007","article-title":"Flexible care in breast cancer","volume":"6","author":"Wardley","year":"2021","journal-title":"ESMO Open"},{"key":"2025101814421500000_13.4.e063242.12","first-page":"430","article-title":"Patients\u2019 experiences of receiving chemotherapy in outpatient clinic and\/or onboard a unique nurse-led mobile chemotherapy unit: a qualitative study","volume":"22","author":"Mitchell","year":"2013","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2025101814421500000_13.4.e063242.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-11-200512060-00008"},{"key":"2025101814421500000_13.4.e063242.14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081491"},{"key":"2025101814421500000_13.4.e063242.15","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.1132"},{"key":"2025101814421500000_13.4.e063242.16","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.20.03609","article-title":"Evaluation of oncology hospital at home: unplanned health care utilization and costs in the huntsman at home real-world trial","volume":"39","author":"Mooney","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025101814421500000_13.4.e063242.17","unstructured":"Genentech Inc, PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) . Prescribing information. 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761170s000lbl.pdf"},{"key":"2025101814421500000_13.4.e063242.18","unstructured":"Roche Registration GmbH, PHESGO (pertuzumab and trastuzumab) . Summary of product characteristics. 2022. Available: https:\/\/www.ema.europa.eu\/documents\/product-information\/phesgo-epar-product-information_en.pdf"},{"key":"2025101814421500000_13.4.e063242.19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025101814421500000_13.4.e063242.20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025101814421500000_13.4.e063242.21","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013503122"},{"key":"2025101814421500000_13.4.e063242.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"2025101814421500000_13.4.e063242.23","first-page":"308","article-title":"Subcutaneous administration of bortezomib: a pilot survey of oncology nurses","volume":"6","author":"Martin","year":"2015","journal-title":"J Adv Pract Oncol"},{"key":"2025101814421500000_13.4.e063242.24","first-page":"4589","article-title":"Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives","volume":"28","author":"Aapro","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025101814421500000_13.4.e063242.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5948"},{"key":"2025101814421500000_13.4.e063242.26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jnci\/djaa083","article-title":"Management of cancer and health after the clinic visit: a call to action for self-management in cancer care","volume":"113","author":"Howell","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025101814421500000_13.4.e063242.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02015"},{"key":"2025101814421500000_13.4.e063242.28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw177"},{"key":"2025101814421500000_13.4.e063242.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.03.004"},{"key":"2025101814421500000_13.4.e063242.30","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.3348","article-title":"Comparing effects in regular practice of e-communication and web-based self-management support among breast cancer patients: preliminary results from a randomized controlled trial","volume":"16","author":"B\u00f8r\u00f8sund","year":"2014","journal-title":"J Med Internet Res"},{"key":"2025101814421500000_13.4.e063242.31","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/pon.4250","article-title":"Psychosocial outcomes of an electronic self-report assessment and self-care intervention for patients with cancer: a randomized controlled trial","volume":"26","author":"Fann","year":"2017","journal-title":"Psycho-Oncology"},{"key":"2025101814421500000_13.4.e063242.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"2025101814421500000_13.4.e063242.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18085"},{"key":"2025101814421500000_13.4.e063242.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830"},{"key":"2025101814421500000_13.4.e063242.35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.2020.38.15_suppl.2083","article-title":"Documentation patterns and impact on observed side effects of the CANKADO eHealth application: an exploratory analysis of the precycle trial","volume":"38","author":"Degenhardt","year":"2020","journal-title":"JCO"},{"key":"2025101814421500000_13.4.e063242.36","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2020.38.15_suppl.2000","article-title":"Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): results of CapRI, a single-center, randomized phase III trial","volume":"38","author":"Mir","year":"2020","journal-title":"JCO"},{"key":"2025101814421500000_13.4.e063242.37","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1200\/OP.20.00639","article-title":"Chemotherapy remote care monitoring program: integration of SMS text patient-reported outcomes in the electronic health record and pharmacist intervention for chemotherapy-induced nausea and vomiting","volume":"17","author":"Hough","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2025101814421500000_13.4.e063242.38","doi-asserted-by":"crossref","first-page":"e1293","DOI":"10.1200\/OP.21.00307","article-title":"Association of a remote patient monitoring (RPM) program with reduced hospitalizations in cancer patients with COVID-19","volume":"17","author":"Pritchett","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2025101814421500000_13.4.e063242.39","first-page":"859","article-title":"AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients","volume":"29","author":"Rasschaert","year":"2021","journal-title":"Support Care Cancer"},{"key":"2025101814421500000_13.4.e063242.40","doi-asserted-by":"crossref","DOI":"10.2196\/18655","article-title":"Digital monitoring and management of patients with advanced or metastatic non-small cell lung cancer treated with cancer immunotherapy and its impact on quality of clinical care: interview and survey study among health care professionals and patients","volume":"22","author":"Schmalz","year":"2020","journal-title":"J Med Internet Res"},{"key":"2025101814421500000_13.4.e063242.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.04.017"},{"key":"2025101814421500000_13.4.e063242.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.6662"},{"key":"2025101814421500000_13.4.e063242.43","first-page":"1607","article-title":"Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up","volume":"26","author":"Kolb","year":"2018","journal-title":"Support Care Cancer"},{"key":"2025101814421500000_13.4.e063242.44","doi-asserted-by":"crossref","first-page":"12000","DOI":"10.1200\/JCO.2021.39.15_suppl.12000","article-title":"Randomized trial of remote cancer symptom monitoring during COVID-19: impact on symptoms, QoL, and unplanned health care utilization","volume":"39","author":"Mooney","year":"2021","journal-title":"JCO"},{"key":"2025101814421500000_13.4.e063242.45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cam4.1002","article-title":"Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT","volume":"6","author":"Mooney","year":"2017","journal-title":"Cancer Med"},{"key":"2025101814421500000_13.4.e063242.46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e13608","article-title":"Real-world implementation and user experience of tailored digital patient monitoring (DPM) modules for patients (PTS) with locally advanced\/metastatic (LA\/M) cancer: early readout analysis from a feasibility study","volume":"40","author":"Jaal","year":"2022","journal-title":"JCO"},{"key":"2025101814421500000_13.4.e063242.47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clinical Trials"},{"key":"2025101814421500000_13.4.e063242.48","doi-asserted-by":"crossref","first-page":"101714","DOI":"10.1016\/j.ejon.2019.101714","article-title":"Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: the symptom navi\u00a9 programme","volume":"44","author":"Bana","year":"2020","journal-title":"Eur J Oncol Nurs"},{"key":"2025101814421500000_13.4.e063242.49","unstructured":"Symptom Navi . Kompetent navigieren und mit Symptomen zurecht kommen [Navigate competently and cope with symptoms]. 2022 Available: https:\/\/symptomnavi.ch\/de\/"},{"key":"2025101814421500000_13.4.e063242.50","unstructured":"EUR-Lex . Council directive of 20 June 1990 on the approximation of the laws of the member states relating to active implantable medical devices. 2022 Available: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:01990L0385-20071011&from=EN"},{"key":"2025101814421500000_13.4.e063242.51","unstructured":"EUR-Lex . Regulation (EU) 2020\/561 of the European Parliament and of the council of 23 April 2020 amending Regulation (EU) 2017\/745 on medical devices, as regards the dates of application of certain of its provisions. 2022. Available: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32020R0561&from=EN"},{"key":"2025101814421500000_13.4.e063242.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"2025101814421500000_13.4.e063242.53","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: what does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025101814421500000_13.4.e063242.54","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V"},{"key":"2025101814421500000_13.4.e063242.55","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025101814421500000_13.4.e063242.56","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2025101814421500000_13.4.e063242.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"2025101814421500000_13.4.e063242.58","unstructured":"National Institutes of Health (NIH), National Cancer Institute . Division of cancer treatment and diagnosis. common terminology criteria for adverse events (CTCAE), Version 5.0. 2022. Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"2025101814421500000_13.4.e063242.59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2016.07.027","article-title":"Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer","volume":"67","author":"Shi","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025101814421500000_13.4.e063242.60","doi-asserted-by":"crossref","DOI":"10.2196\/17898","article-title":"Follow-up of cancer patients receiving anti-PD-(L)1 therapy using an electronic patient-reported outcomes tool (kiss): prospective feasibility cohort study","volume":"4","author":"Iivanainen","year":"2020","journal-title":"JMIR Form Res"},{"key":"2025101814421500000_13.4.e063242.61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3314"},{"key":"2025101814421500000_13.4.e063242.62","article-title":"Phase III study of the European organisation for research and treatment of cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7)","volume":"27","author":"Br\u00e9dart","year":"2018","journal-title":"Eur J Cancer Care (Engl)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:42:28Z","timestamp":1760823748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,19]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/bmjopen-2022-063242"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063242","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}